International Conferences

Recommended Conferences for Under Venom Immunotherapy

Under Venom Immunotherapy

As per available reports about 2 relevant journals, 1 Conferences, 1 workshops are presently dedicated exclusively to under venom immunotherapy and about 2,070 articles are being published on under venom immunotherapy. 

Under venom immunotherapy:

1. Insect venom immunotherapy (VIT) is the injection, under the skin, of gradually incrementing doses of insect venom. VIT commences with a minutely minuscular dose that is gradually incremented. This process causes a transmutation in how the immune system responds to the venom.
2. There is a high caliber of scientific evidence to show that VIT obviates rigorous allergic reactions (anaphylaxis) to insect stings, with the aim of obviating morbidity and death. More than 30 years experience has perceived it to be efficacious, well abode, safe when administered in opportune settings and associated with an amelioration in quality of life for patients.
3. Different insect venoms are associated with different risks of allergic reaction to the VIT injections themselves. In this regard, Jack Jumper Ant (JJA) VIT appears to be kindred to honeybee VIT.
4. Any clinical accommodation that is competent to distribute honeybee VIT is additionally competent to distribute JJA VIT. The same protocols used to administer honeybee VIT can be applied to JJA VIT.
5. The protocols of administration associated with the lowest risks of allergic reactions to VIT are the more gradual outpatient ("conventional" and "semirush") approaches.
6. Expedited inpatient approaches ("rush" and "ultrarush") may be utilized, but these present higher risks of allergic reactions. Patients offered expedited inpatient treatment should be conscientiously culled so as to omit those at greatest risk of decompensating during a reaction.
7. There is a jeopardy of allergic reactions to VIT injections. Emergency procedures and experience with treating anaphylaxis must be in place for the treatment of these reactions. This applies to all forms of injection immunotherapy, not just JJA VIT.
8. JJA VIT is unique because the JJA is found only in Australia. The number of patients affected on a worldwide substratum is therefore minute. This presents a quandary for the manufacture and supply of venom extract because there is no “economy of scale”.
9. At present, JJA venom is only available as an Active Pharmaceutical Ingredient (API), i.e. in concentrated form. This restricts its use to allergy accommodations that are able to manage formulation, storage and dispensing on-site.
10. Where there are constrained resources for providing JJA VIT, allergy accommodations should prioritise available treatment places for patients that (i) have had documented hypotensive or hypoxaemic reactions requiring emergency medical treatment, and (ii) have an perpetual risk of fortuitous stings.

Hymenoptera venom allergy is an immunoglobulin E (IgE)- mediated hypersensitivity to the venom of insects in the insect order Hymenoptera. This allergic reaction may be caused by stings from a number of species in this insect order, occurring only in epersons who have previously been sensitized to Hymenoptera venom
 

OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide. 

Global allergy diagnostic and treatment of undervenom immunotherapy market is projected to increase to nearly $35.3 billion by 2015 from $31.5 billion in 2014. This market is expected to reach $46.8 billion by 2020, corresponding to a compound annual growth rate (CAGR) of 5.8% during 2015 to 2020 period.

Conferences :

• Protein Engineering Conference
  October 26-28, 2015 Chicago, USA
• 7^th Vaccines Middle East Conference
  September 28-29, 2015 Dubai, UAE
• 13^th  Vaccines Asia Pacific Conference
  November 10-12, 2016 Melbourne, Australia
•  9^th Vaccines 2015
  November 30-December 02, 2015 San Francisco, USA
•  10^th Euro Vaccines Conference
  June 16-18, 2016 Rome, Italy.
•  Hepatities Vaccines Conference
  June 16-18, 2016 Rome, Italy
•  Hiv Vaccines Conference
  Oct 3-5, 2016 Miami, USA
• Vaccines USA Conference
  November 30-December 02, 2015 San Francisco, USA
• 7^th Proteomics Conference
  October 10-12, 2016 Rome, Italy
• 6^th World Proteomics Conference
  March 29-30, 2016 Atlanta, USA
• VTH-2015
  November 02-04, 2015 HICC, Hyderabad, India
• Travel Medicine & Vaccines
  May 9-11, 2016 San Francisco, USA
• H1N1 & Influenza Vaccines
  July 25-26, 2016 Chicago, USA
• Children Vaccines 2016
  Oct 10-12, 2016 Rome, Italy
• Mucosal Immunology
  July 28-29, 2016 Melbourne, Australia
• 4^th Immunology conference
  September 28-30, 2015 Houston, Texas, USA
• Tumour Immunology and Immunotherapy
  July 28-30, 2016 Melbourne, Australia
• 2^nd Neuroimmunology and Therapeutics
  March 31-April 02, 2016 Atlanta, USA
• Twenty-Second Conference on Proteins
• 10th Proteins Conference
• Medical Proteomics Conference
• Protein Application Conference

Socities :

• Vaccination Clinics - Humane Society of Broward County
• Vaccine Clinics - Connecticut Humane Society
• Vaccine Clinics | Wisconsin Humane Society
• Australian Vaccinologists society
• The american Vaccines and vaccination society.
• US Immunology society.
• World immunization Association
• American Immunologists association.
• North California medical society

Companies :

• RMS MS Contin
• Endo Pharmaceuticals
• Carbex.
• Benforce M
• Minitide
• Reglide
• Rezult.
• Zolmelis
• Jalra
• Chromet

This page will be updated regularly.

This page was last updated on April 19, 2024